"Survival Rate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
| Descriptor ID |
D015996
|
| MeSH Number(s) |
E05.318.308.985.550.900 N01.224.935.698.826 N06.850.505.400.975.550.900 N06.850.520.308.985.550.900
|
| Concept/Terms |
Survival Rate- Survival Rate
- Rate, Survival
- Rates, Survival
- Survival Rates
Mean Survival Time- Mean Survival Time
- Mean Survival Times
- Survival Time, Mean
- Survival Times, Mean
- Time, Mean Survival
- Times, Mean Survival
Cumulative Survival Rate- Cumulative Survival Rate
- Cumulative Survival Rates
- Rate, Cumulative Survival
- Rates, Cumulative Survival
- Survival Rate, Cumulative
- Survival Rates, Cumulative
|
Below are MeSH descriptors whose meaning is more general than "Survival Rate".
Below are MeSH descriptors whose meaning is more specific than "Survival Rate".
This graph shows the total number of publications written about "Survival Rate" by people in this website by year, and whether "Survival Rate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Survival Rate" by people in Profiles.
-
Cervical Lymph Node Invasion in Pediatric Salivary Gland Malignancies: Clinical Overview and Therapeutic Implications. Pediatr Blood Cancer. 2025 Apr; 72(4):e31581.
-
Temporal trends in pediatric cancer mortality: rare cancers lag behind more common cancers. Pediatr Hematol Oncol. 2025 Feb; 42(1):1-13.
-
A Multi-Center International Analysis of Lung Transplantation Outcomes in Patients With COVID-19. Clin Transplant. 2024 Sep; 38(9):e15462.
-
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer. 2023 04 01; 129(7):1051-1063.
-
Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunol Immunother. 2021 Apr; 70(4):1101-1113.
-
18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. 2020 Aug; 69(8):1519-1534.
-
The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019 04 01; 125(7):1155-1162.
-
Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. Cancer Res. 2018 01 15; 78(2):451-462.
-
Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer. Oncotarget. 2017 Mar 21; 8(12):19645-19660.
-
N-Acetyl Cysteine Therapy Does Not Prevent Renal Failure in High-Risk Patients Undergoing Open-Heart Surgery. Heart Surg Forum. 2016 Feb 22; 19(1):E16-22.